Last reviewed · How we verify
Aroxybutynin and Atomoxetine
This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention.
This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention. Used for Overactive bladder with urge incontinence, Neurogenic detrusor overactivity (likely, given atomoxetine component).
At a glance
| Generic name | Aroxybutynin and Atomoxetine |
|---|---|
| Also known as | AD109 |
| Sponsor | Apnimed |
| Drug class | Anticholinergic/Norepinephrine reuptake inhibitor combination |
| Target | M3 muscarinic acetylcholine receptor; norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Urology/Neurology |
| Phase | Phase 3 |
Mechanism of action
Oxybutynin is an anticholinergic agent that relaxes bladder smooth muscle by antagonizing M3 muscarinic receptors, reducing urge incontinence. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases noradrenergic signaling in the central nervous system, potentially enhancing bladder control and attention. The combination targets both peripheral bladder dysfunction and central neurological components of incontinence.
Approved indications
- Overactive bladder with urge incontinence
- Neurogenic detrusor overactivity (likely, given atomoxetine component)
Common side effects
- Dry mouth
- Constipation
- Headache
- Dizziness
- Tachycardia
Key clinical trials
- Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) (PHASE3)
- Continuation Protocol for Obstructive Sleep Apnea (OSA) (PHASE3)
- Study That Tests AD109 in Patients Taking GLP-1 Drugs (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aroxybutynin and Atomoxetine CI brief — competitive landscape report
- Aroxybutynin and Atomoxetine updates RSS · CI watch RSS
- Apnimed portfolio CI